Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

NCT02629692 is registered in ClinicalTrials.gov with Sun Pharma Advanced Research Company Limited as lead sponsor.

NCT NCT02629692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02629692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Lead sponsor
Sun Pharma Advanced Research Company Limited
Phase
Phase 1/2
Overall status
Terminated
Start date
June 27, 2016
Completion date
January 3, 2025
Enrollment
124 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia (for part b and c), healthy (for part a)